Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

Gerd Döring, Patrick Flume, Harry Heijerman, J Stuart Elborn, for the Consensus Study Group

Research output: Contribution to journalArticle

289 Citations (Scopus)

Abstract

In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.
Original languageEnglish
Pages (from-to)461-479
Number of pages19
JournalJournal of Cystic Fibrosis
Volume11
Issue number6
DOIs
Publication statusPublished - Dec 2012

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Treatment of lung infection in patients with cystic fibrosis: Current and future strategies'. Together they form a unique fingerprint.

Cite this